Phase 1/2 × Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1/2 Completed
55 enrolled 17 charts
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Phase 1/2 Completed
97 enrolled 43 charts
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Phase 1/2 Completed
803 enrolled 2 FDA
KEYNOTE145
Phase 1/2 Completed
161 enrolled 29 charts
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Phase 1/2 Completed
55 enrolled
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Phase 1/2 Completed
32 enrolled 9 charts
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 Completed
713 enrolled 1 FDA
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Phase 1/2 Completed
66 enrolled 13 charts
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Phase 1/2 Completed
11 enrolled 12 charts
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Phase 1/2 Completed
29 enrolled
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Phase 1/2 Completed
49 enrolled 12 charts
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Phase 1/2 Completed
24 enrolled 16 charts
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Phase 1/2 Completed
41 enrolled
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 1/2 Completed
60 enrolled 32 charts
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1/2 Completed
20 enrolled 9 charts
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase 1/2 Completed
58 enrolled 18 charts
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Phase 1/2 Completed
18 enrolled 13 charts
PDX+Romi
Phase 1/2 Completed
57 enrolled
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
39 enrolled
Ublituximab + Ibrutinib in Select B-cell Malignancies
Phase 1/2 Completed
66 enrolled
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Phase 1/2 Completed
204 enrolled 27 charts
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Phase 1/2 Completed
260 enrolled 33 charts
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 Completed
20 enrolled
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Phase 1/2 Completed
43 enrolled 19 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
ENHANCE
Phase 1/2 Completed
47 enrolled 15 charts
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Phase 1/2 Completed
32 enrolled
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
Phase 1/2 Completed
38 enrolled
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Phase 1/2 Completed
79 enrolled 13 charts
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Phase 1/2 Completed
28 enrolled
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Phase 1/2 Completed
27 enrolled 15 charts
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Phase 1/2 Completed
100 enrolled
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Phase 1/2 Completed
22 enrolled 9 charts
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Phase 1/2 Completed
124 enrolled 10 charts
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1/2 Completed
40 enrolled 14 charts
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Phase 1/2 Completed
30 enrolled 9 charts
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1/2 Completed
76 enrolled 11 charts
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Phase 1/2 Completed
6 enrolled
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Phase 1/2 Completed
21 enrolled
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Phase 1/2 Completed
37 enrolled
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Phase 1/2 Completed
106 enrolled
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Completed
103 enrolled 12 charts
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Phase 1/2 Completed
13 enrolled
LLC0606
Phase 1/2 Completed
42 enrolled 11 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Phase 1/2 Completed
18 enrolled 8 charts
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
Phase 1/2 Completed
23 enrolled 26 charts
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Phase 1/2 Completed
36 enrolled 14 charts
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Phase 1/2 Completed
148 enrolled
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts